RTGN — what changed in the latest 10-Q
A section-by-section comparison of RTGN's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-20
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +13 | −11 | ~8 | 35 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 4 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | Some risk factors updated | 0 | 0 | ~4 | 4 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
The following table sets forth key components of our results of operations for the three months ended June 30, 2026 and 2025.
We did not recognize revenues for the three months ended June 30, 2026 and 2025.
Research and development expenses increased by $51,976, or 360%, to $66,406 for the three months ended June 30, 2026 from $14,430 for the three months ended June 30, 2025. The increase was primarily the result of engaging engineering and technology consultants to work on the RetinalCam project.
Stock-based compensation expenses decreased by $225,407 or 90%, to $24,782 for the three months ended June 30, 2026 from $250,189 for the three months ended June 30, 2025. The decrease was primarily due to the recognition of expense for options issued in the first quarter of 2025 and which had a sig…
General and administrative expenses decreased by $171,475 or 45%, to $212,254 for the three months ended June 30, 2026 from $383,729 for the three months ended June 30, 2025. Administrative costs consisting of costs related to the services provided by the executive from Sanovas, were allocated based…
Text removed vs the prior filing · source: 10-Q · 2026-05-20
We are actively pursuing our mission to prevent vision loss and blindness due to ocular diseases, including diabetic retinopathy and maculopathy, in ourfirst two devices:
We intend to launch RetinalCamTM in the fourth quarter of 2026.
Comparison of the three months ended March 31, 2026 and 2025
The following table sets forth key components of our results of operations for the three months ended March 31, 2026 and 2025.
We did not recognize revenues for the three months ended March 31, 2026 and 2025.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice